Vidhi Specialty Food Ingredients Limited has informed the Exchange about Transcript

Vidhi delivered resilient FY26 performance despite a challenging macro environment with revenue flat at INR380 crores (vs INR382.3 crores YoY), while EBITDA rose 14.7% to INR78 crores and margins expanded sharply from 17.91% to 20.52%. Net profit grew 10.80% to INR49.15 crores. The CFO highlighted that manufacturing EBITDA margins are already ~24-25% on the INR330 crore manufacturing sales base. Management guided that high-value/value-added products currently at ~5% of portfolio will double to ~10-12% in FY27, driving further margin improvement. Two new capex projects were disclosed: CoatIcon (pharma tablet coating, INR5-12 crores) and a new product line at Dahej (INR75-85 crores phase 1 capex, targeting INR125-150 crores revenue, commissioning mid-FY27-28). The company expects full capacity utilisation of both Roha and Dahej facilities in FY27. Management flagged that the withdrawal of the export finance subvention scheme from December 2025 increased finance costs, with interest coverage ratio declining from 28.27% to 16.75%.